Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?

On 7 June(,) the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.

Detalles Bibliográficos
Autores principales: Lalli, Giovanna, Schott, Jonathan M, Hardy, John, De Strooper, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350893/
https://www.ncbi.nlm.nih.gov/pubmed/34338436
http://dx.doi.org/10.15252/emmm.202114781
_version_ 1783735867500658688
author Lalli, Giovanna
Schott, Jonathan M
Hardy, John
De Strooper, Bart
author_facet Lalli, Giovanna
Schott, Jonathan M
Hardy, John
De Strooper, Bart
author_sort Lalli, Giovanna
collection PubMed
description On 7 June(,) the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.
format Online
Article
Text
id pubmed-8350893
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83508932021-08-15 Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? Lalli, Giovanna Schott, Jonathan M Hardy, John De Strooper, Bart EMBO Mol Med Commentary On 7 June(,) the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain. John Wiley and Sons Inc. 2021-08-02 2021-08-09 /pmc/articles/PMC8350893/ /pubmed/34338436 http://dx.doi.org/10.15252/emmm.202114781 Text en © 2021 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Lalli, Giovanna
Schott, Jonathan M
Hardy, John
De Strooper, Bart
Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
title Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
title_full Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
title_fullStr Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
title_full_unstemmed Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
title_short Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
title_sort aducanumab: a new phase in therapeutic development for alzheimer’s disease?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350893/
https://www.ncbi.nlm.nih.gov/pubmed/34338436
http://dx.doi.org/10.15252/emmm.202114781
work_keys_str_mv AT lalligiovanna aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease
AT schottjonathanm aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease
AT hardyjohn aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease
AT destrooperbart aducanumabanewphaseintherapeuticdevelopmentforalzheimersdisease

Ejemplares similares